ELGN EYE
Alternative Names: ELGN-EYELatest Information Update: 28 Jul 2024
At a glance
- Originator Elgan Pharma
- Class Coenzymes; Eye disorder therapies; Insulins; Omega 3 fatty acids
- Mechanism of Action Angiogenesis modulating agents; Antioxidants; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinopathy of prematurity